Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB - Free Report) from a sell rating to a hold rating in a research report report published on Friday morning.

Other equities analysts also recently issued research reports about the stock. Chardan Capital reiterated a "buy" rating and issued a $1.25 price target on shares of Seres Therapeutics in a report on Wednesday, November 13th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $5.08.

Seres Therapeutics Stock Down 0.2 %

MCRB stock traded down $0.00 on Friday, reaching $0.83. 1,230,124 shares of the company's stock were exchanged, compared to its average volume of 1,742,649. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $1.53. The stock has a fifty day moving average of $0.85 and a 200-day moving average of $0.86. The firm has a market cap of $141.92 million, a PE ratio of -3.61 and a beta of 2.11.

Institutional Investors Weigh In On Seres Therapeutics

A number of large investors have recently added to or reduced their stakes in MCRB. Virtu Financial LLC lifted its holdings in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC raised its position in shares of Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock worth $93,000 after purchasing an additional 22,250 shares during the last quarter. Avantax Advisory Services Inc. lifted its stake in Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after buying an additional 28,500 shares in the last quarter. Jane Street Group LLC grew its holdings in Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after buying an additional 37,866 shares during the last quarter. Finally, State Street Corp increased its position in Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after buying an additional 43,700 shares in the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.